Condition
Gaucher's Disease Type I
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Imiglucerase Gz437843
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Phase 1 (1)
Phase 3 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT03485677Phase 3CompletedPrimary
Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3
NCT06143904Phase 1CompletedPrimary
A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants
Showing all 2 trials
Research Network
Common Treatments
- Imiglucerase Gz4378431
- Eliglustat Gz3856601
- Eliglustat Tartrate1
- 14cgenz1126381
Active Sponsors
- Sanofi2
- Genzyme Corp.1
Related Conditions
- Gauchers Disease Type Iii1
- Gauchers Disease Type I Gauchers Disease Type Iii1